| USGOV-DEPARTMENT-OF-DEFENSE |
USGOV-DEPARTMENT-OF-DEFENSE |
95%
|
USAspending awards from Department of Defense: $150,400 across 1 awards. W81K0023F0175 AFIRMA GENOMIC SEQUENCING CLASSIFIER LABORATORY TESTING | Qwen corrected direction: Explicit Department of Defen… |
| USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS |
USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS |
95%
|
USAspending awards from Department of Veterans Affairs: $2,669,809 across 9 awards. 36C25726N0108 THYROID MOLECULAR GENOMIC TESTING; 36C24723P0403 AFIRMA GSC CPT 81546 AND 0204U; 36C25722P0705 VERACY… |
| MEDICAID |
MEDICAID |
90%
|
Medicaid accounted for 1%, 1%, and 3% of our testing revenue. |
| MEDICARE |
MEDICARE |
90%
|
The Company's total third-party payers and other customers in excess of 10% of total revenue and their related revenue as a percentage of total revenue were as follows: Three Months Ended March 31, 2… |
| PRIVATE-COMMERCIAL-PAYERS |
PRIVATE-COMMERCIAL-PAYERS |
90%
|
Private commercial payers, including Medicare advantage, accounted for 66%, 64%, and 61% of our testing revenue. |
| UNITEDHEALTHCARE |
UNITEDHEALTHCARE |
90%
|
The Company's total third-party payers and other customers in excess of 10% of total revenue and their related revenue as a percentage of total revenue were as follows: Three Months Ended March 31, 2… |
| HOSPITAL-AND-LABORATORY-CUSTOMERS |
HOSPITAL-AND-LABORATORY-CUSTOMERS |
80%
|
For our IVD tests, we bill hospital and laboratory customers directly for test kits they order. |
| EXAS |
Exact Sciences Corp |
72%
|
Reciprocal relationship from EXAS graph: Reciprocal relationship from VCYT graph: Reciprocal relationship from EXAS graph: Reciprocal relationship from VCYT graph: y requirements, which may be subjec… |
| EXAS |
Exact Sciences Corp |
72%
|
y requirements, which may be subject to change, and our failure to comply with these requirements could substantially harm our business. Certain of our products are regulated as IVD MDs, including Pr… |
| GH |
Guardant Health, Inc. |
72%
|
y requirements, which may be subject to change, and our failure to comply with these requirements could substantially harm our business. Certain of our products are regulated as IVD MDs, including Pr… |
| GH |
Guardant Health, Inc. |
72%
|
Reciprocal relationship from GH graph: Reciprocal relationship from VCYT graph: Reciprocal relationship from GH graph: Reciprocal relationship from VCYT graph: Reciprocal relationship from GH graph: … |
| MYGN |
Myriad Genetics, Inc. |
72%
|
Reciprocal relationship from MYGN graph: Reciprocal relationship from VCYT graph: y requirements, which may be subject to change, and our failure to comply with these requirements could substantially… |
| MYGN |
Myriad Genetics, Inc. |
72%
|
y requirements, which may be subject to change, and our failure to comply with these requirements could substantially harm our business. Certain of our products are regulated as IVD MDs, including Pr… |
| QGEN |
Qiagen N.V. |
72%
|
y requirements, which may be subject to change, and our failure to comply with these requirements could substantially harm our business. Certain of our products are regulated as IVD MDs, including Pr… |
| QGEN |
Qiagen N.V. |
72%
|
Reciprocal relationship from QGEN graph: Reciprocal relationship from VCYT graph: y requirements, which may be subject to change, and our failure to comply with these requirements could substantially… |
| TMO |
Thermo Fisher Scientific Inc. |
72%
|
y requirements, which may be subject to change, and our failure to comply with these requirements could substantially harm our business. Certain of our products are regulated as IVD MDs, including Pr… |
| TMO |
Thermo Fisher Scientific Inc. |
72%
|
Reciprocal relationship from TMO graph: Reciprocal relationship from VCYT graph: Reciprocal relationship from TMO graph: Reciprocal relationship from VCYT graph: Reciprocal relationship from TMO grap… |
| C2I-GENOMICS-INC |
C2I-GENOMICS-INC |
62%
|
eriod audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial… |
| C2I-GENOMICS-LTD |
C2I-GENOMICS-LTD |
62%
|
probable of being reached and estimates the amount to be included in the transaction price. Milestone payments that are not within either party’s control, such as non-operational developmental and re… |
| CALDEROME-INC-CALDEROME-INC |
CALDEROME-INC-CALDEROME-INC |
62%
|
eriod audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial… |
| CAPITAL-RESOURCES |
CAPITAL-RESOURCES |
62%
|
headcount and annual merit increases also increased. Spend supporting direct research and product development expense related to our ongoing development costs for our CLIA tests and MRD strategies in… |
| SONIC-HEALTHCARE-USA-INC |
SONIC-HEALTHCARE-USA-INC |
62%
|
ts): Three Months Ended March 31, 2026 2025 Numerator for basic and diluted EPS — net income (A) $ 28,707 $ 7,047 Denominator for basic EPS — weighted average shares (B) 79,537 78,028 Effect of poten… |
| SPECIFIC-GROUP |
SPECIFIC-GROUP |
62%
|
ate device is available and the devices do not fall within an existing 510(k)-exempt classification, an applicant may submit a de novo request to down classify the device into Class II or Class I, wh… |
| UNITEDHEALTHCARE-GROUP |
UNITEDHEALTHCARE-GROUP |
62%
|
sement for our tests, our revenue could decline. We receive a significant portion of our revenue from a limited number of third-party payers, some of which have not contracted with us to be a partici… |
